Vivos Therapeutics posted Q2 revenue of $5.2 million, up 35% from a year earlier, as service revenue climbed to $3.8 million.
Net loss widened to $5.52 million, while loss per share narrowed to $0.31.
Gross margin rose 2 percentage points to 57%, while operating loss held roughly flat at $4.83 million.
Cash and cash equivalents fell to $1.77 million at June 30, while stockholders’ equity deficit widened to $3.82 million.
CEO Kirk Huntsman cited rising referrals and program revenue in Nevada centers, progress on SCN’s AI-enabled software conversion, and expanded capacity.
VVOS•
